Business Segments Virax Biolabs Group Limited
Equities
VRAX
KYG9495L1251
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2145 USD | +3.62% |
|
-5.80% | -37.97% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
Healthcare Equipment Distribution | ||||||
Distribution of Diagnostics Test Kits and PPE Products | 124K | - | 8.56K | 156K | 6.33K | |
Total Assets | 39.62K | 48.71K | 9.81M | 5.48M | 6.43M | |
Interest Expense | -28.64K | -15.44K | -15.47K | -26.88K | -58.18K | |
Income Tax Expense | - | - | - | - | -137K | |
CAPEX | - | - | -178K | -952K | -604K | |
EBT | -673K | -1.75M | -5.46M | -6.74M | -6.2M | |
Gross Profit | -9.43K | - | -1.36K | 50.59K | -53.07K | |
D&A | - | - | - | 103K | 333K | |
Operating Income | -645K | -1.73M | -5.73M | -6.5M | -6.16M | |
Net Income | -651K | -1.71M | -5.46M | -6.73M | -6.06M |
Geographical Revenue Distribution History
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
United Kingdom | - | - | 8.56K | 156K | 6.33K | |
Total Assets | - | 48.71K | 9.81M | 5.48M | 6.43M | |
Interest Expense | - | -15.44K | -15.47K | -26.88K | -58.18K | |
Income Tax Expense | - | - | - | - | -137K | |
D&A | - | - | - | 103K | 333K | |
CAPEX | - | - | -178K | -952K | -604K | |
Gross Profit | - | - | -1.36K | 50.59K | -53.07K | |
Net Income | - | -1.71M | -5.46M | -6.73M | -6.06M | |
EBT | - | -1.75M | -5.46M | -6.74M | -6.2M | |
Operating Income | - | -1.73M | -5.73M | -6.5M | -6.16M |
- Stock Market
- Equities
- VRAX Stock
- Financials Virax Biolabs Group Limited
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition